We can’t show the full text here under this license. Use the link below to read it at the source.
Adverse event comparison between glucagon‐like peptide‐1 receptor agonists and other antiobesity medications following bariatric surgery
Side effects of weight-loss drugs with glucagon-like peptide-1 action compared to other drugs after weight-loss surgery
AI simplified
Abstract
Among 599 patients who underwent bariatric surgery, GLP-1 receptor agonists were not associated with higher odds of adverse events.
- The median age of the patients was 47.8 years, with 83% identifying as female.
- The median time from surgery to the initiation of antiobesity medications was 30 months.
- Using GLP-1 receptor agonists did not show a significantly higher risk of adverse events, with adjusted odds ratios of 1.1.
- Initiating antiobesity medications 12 months or more after surgery was associated with a significantly lower risk of adverse events.
AI simplified
Key numbers
1.1
Odds of Adverse Events
Adjusted odds ratio for GLP-1RA vs. non-GLP-1RA AOMs
0.01
Lower Odds of Any
Odds ratio for AOM initiation ≥12 months after surgery vs. <12 months
21%
Total Body Weight Loss
Weight loss at 12 months after AOM initiation